Nuclear medicine operations may soon enjoy steadier flows of certain in-demand radioisotopes. If so, much credit will go to companies that had the strategic sense to collaborate with each other.
By identifying these structural changes prior to the onset of symptomatic neurodegeneration, providers may be able to initiate preventive therapies sooner.